A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(14 sites) China
Peking University Third Hospital, Beijing, Beijing Municipality Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Harbin Medical University Cancer Hospital, Haerbin, Heilongjiang Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan Renmin Hospital of Wuhan University, Wuhan, Hubei Hunan Cancer Hospital, Changsha, Hunan Qilu Hospital of Shandong University, Jinan, Shandong The Affiliated Hospital of Qingdao University, Qingdao, Shandong Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality First Hospital of Shanxi Medcial University, Taiyuan, Shanxi West China Hospital of Sichuan University, Chengdu, Sichuan The Second Hospital of Tianjin Medical University, Tianjin, Tianjin Municipality
Key details Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd.
Collaborators
Shanghai Xianxiang Medical Technology Co., Ltd.
Enrollment target
~152 participants
Primary completion
January 2027
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Age range
18 Years and older
Last updated January 2025